

VEGA DAILY

Unlock Your Best Quote
Ask VEGA Now!

September 30, 2026

VITAMIN

01

- The Vitamin B1 market remained weak this month. Mainstream producers continued to hold prices firm, and deliveries remained tight. However, demand was moderate, with purchasing and sales roughly balanced. Channel prices have recently stabilized as low-priced inventories were gradually depleted. Current market quotes are around USD 30.4/kg for Vitamin B1 Mononitrate and USD 37/kg for Vitamin B1 Hydrochloride.
- Evonik has rejected BASF's approximately EUR 10.3 billion acquisition offer, considering it insufficient to initiate formal negotiations. Further discussions remain possible.

AMINO ACID

02

- Threonine FOB quotations have recently fallen to around USD 920-940/MT. China exported 51,000 MT of Threonine in August, down 11.1% month-on-month but up 2.8% year-on-year. January–August exports totaled 487,000 MT, up 5.9% year-on-year.
- Cargill plans to invest over USD 130 million in the next two years to expand its poultry business in Asia, mainly in Thailand and the Philippines, to meet growing protein demand and strengthen supply chain resilience, food safety, quality, and innovation.

API

03

- Jiangxi Chamger Pharmaceutical is planning a technical upgrade project with annual capacity of 375 MT of pharmaceutical intermediates and 100 MT of Hydrocortisone intermediates, with a total investment of RMB 73.82 million. The first phase will mainly produce 60 MT/year of Cortisone Acetate intermediates and 40 MT/year of Hydrocortisone intermediates.
- Guobang Pharma announced that its Fluralaner API jointly developed by its subsidiary Zhejiang Guobang and other partners has been approved by China's Ministry of Agriculture and Rural Affairs as a Class II new veterinary drug, with a four-year monitoring period. The API is mainly used in ectoparasite control products for dogs and cats.

FOOD ADDITIVE

04

COFCO Biotechnology plans to invest RMB 70 million in its indirect wholly owned subsidiary in Yushu, Jilin, to support construction of its D-Allulose project. Following the capital increase, the company will continue to control 100% of the subsidiary's equity.

Reported by Shea, Sharon and Faye

ONE STOP SOLUTION SUPPLIER



www.vegapharma.com

www.vegafeed.com

www.prumix.com

